• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK 3 Star

Last Price$56.26Day Change (%)0.37%
Open Price$56.45Day Change ($)0.21
Day Range55.93–56.9552-Week Range44.60–58.14

As of Wed 04/16/2014 03:44 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck ’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection

    Merck ’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection

  2. Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection

    Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection

  3. Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck ’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014

    Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck ’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014

  4. Merck CEO Frazier: Consumer Unit Draws 'Substantial' Interest -Fox News

    Merck CEO Frazier: Consumer Unit Draws 'Substantial' Interest -Fox News

  5. Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others

    Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others

  6. Smooth Transitions

    These managers have planned for the future—and protected strong records—by placing an emphasis on succession planning.

  7. Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients ...

    Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...

  8. Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29

    Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29

  9. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.